1. Male or female patients aged between 18 and 65 years (both Inclusive). <br/ >2. Patients with laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 2 days of randomization. <br/ >3. Patients havingPneumonia with no signs of severe disease with SpO2 â?¤94% (range 90-94%) on room air. <br/ >4. Patients with any two of the following signs or symptoms suggestive of COVID-19. <br/ > - Fever <br/ > - Cough <br/ > - dyspnoea or hypoxia <br/ > - Respiratory rate more or equal to 24 per minute. <br/ >5. Radiographic infiltrates as confirmed by imaging (chest xray). <br/ >6. Patients who are willing to sign written informed consent for participation in the study and willing to adhere to all protocol procedures. <br/ >7. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.

1. Male or female patients aged between 18 and 65 years (both Inclusive). <br/ >2. Patients with laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 2 days of randomization. <br/ >3. Patients havingPneumonia with no signs of severe disease with SpO2 â?¤94% (range 90-94%) on room air. <br/ >4. Patients with any two of the following signs or symptoms suggestive of COVID-19. <br/ > - Fever <br/ > - Cough <br/ > - dyspnoea or hypoxia <br/ > - Respiratory rate more or equal to 24 per minute. <br/ >5. Radiographic infiltrates as confirmed by imaging (chest xray). <br/ >6. Patients who are willing to sign written informed consent for participation in the study and willing to adhere to all protocol procedures. <br/ >7. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.

1. Male or female patients aged between 18 and 65 years (both Inclusive). <br/ >2. Patients with laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 2 days of randomization. <br/ >3. Patients havingPneumonia with no signs of severe disease with SpO2 â?¤94% (range 90-94%) on room air. <br/ >4. Patients with any two of the following signs or symptoms suggestive of COVID-19. <br/ > - Fever <br/ > - Cough <br/ > - dyspnoea or hypoxia <br/ > - Respiratory rate more or equal to 24 per minute. <br/ >5. Radiographic infiltrates as confirmed by imaging (chest xray). <br/ >6. Patients who are willing to sign written informed consent for participation in the study and willing to adhere to all protocol procedures. <br/ >7. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.

1. Male or female patients aged between 18 and 65 years (both Inclusive). <br/ >2. Patients with laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 2 days of randomization. <br/ >3. Patients havingPneumonia with no signs of severe disease with SpO2 â?¤94% (range 90-94%) on room air. <br/ >4. Patients with any two of the following signs or symptoms suggestive of COVID-19. <br/ > - Fever <br/ > - Cough <br/ > - dyspnoea or hypoxia <br/ > - Respiratory rate more or equal to 24 per minute. <br/ >5. Radiographic infiltrates as confirmed by imaging (chest xray). <br/ >6. Patients who are willing to sign written informed consent for participation in the study and willing to adhere to all protocol procedures. <br/ >7. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.